The ingredients of Congsheng Capsules including the root of Poly gonum multiflorum, the leaf of Nelumbo nucifera, the stem of Cistanche deserticola, an d the body of the earthworm were identified by thin-layer chromatography. The r e sults showed that the chromatographic spots of the four ingredients were distinc t with good reappearance, and could be used for the identification of this kind of medical preparation.

A HPLC method was established for determining the content of bai calin in Qinxiazhixiao Instant Granules. The specification of the YWG-C18 chrom atograp hic column was 4.6 mm×250 mm, 10 μm; the mobile phase was MeOH∶H2O∶THF∶H 3P O4 (200∶300∶50∶0.16); the retention time of baicalin was about 9 minutes; t he average recovery rate of baicalin was 100.65%; and the RSD 2.03%.

Background::Single-tablet regimen (STR) provides a convenient once-daily regimen for the prevention of human immunodeficiency virus (HIV) infection. Here, we investigated the safety and tolerability of coformulated bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) as a three-drug, STR for post-exposure prophylaxis (PEP) in Chinese individuals.Methods::This was a prospective, open-label, single-arm trial conducted in a sexually transmitted diseases and acquired immunodeficiency syndrome clinic of a tertiary hospital in Beijing, China. Adults requiring PEP were prescribed BIC/FTC/TAF one pill once a day for 28 days. Clinical and laboratory data were collected and analyzed at baseline, weeks 2, 4, 8, 12, and 24.Results::Of 112 participants enrolled in the study, 109 (97.3%) were male and the mean age was 30 ± 8 years. PEP completion was 96.4% (95% confidence interval: 91.1-99.0%). Two participants stopped PEP after 2 days because the source partner was identified as HIV uninfected. One participant was excluded due to hepatitis B virus infection according to the exclusion criteria. One discontinued due to the participant’s decision. No participant acquired HIV through week 24. Adherence was 98.9% (standard deviation [SD]: 3.3%) by self-reporting and 98.5% (SD: 3.5%) by pill count. Only five participants experienced mild clinical adverse events attributed to the study drug (including headache, diarrhea, and nausea) and four participants had elevated serum creatinine (grade 1).Conclusions::A once daily, STR of BIC/FTC/TAF used as PEP was safe and well-tolerated with a high rate of completion and adherence in Chinese. BIC/FTC/TAF may be a good option for PEP.Trial Registration::ChiCTR.org.cn, ChiCTR2100048080